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Background: Noonan syndrome is an autosomal dominant developmental disorder with a high phenotypic variability,
which shares clinical features with other rare conditions, including LEOPARD syndrome, cardiofaciocutaneous
syndrome, Noonan-like syndrome with loose anagen hair, and Costello syndrome. This group of related disorders,
so-called RASopathies, is caused by germline mutations in distinct genes encoding for components of the RAS-MAPK
signalling pathway. Due to high number of genes associated with these disorders, standard diagnostic testing requires
expensive and time consuming approaches using Sanger sequencing. In this study we show how targeted Next
Generation Sequencing (NGS) technique can enable accurate, faster and cost-effective diagnosis of RASopathies.
Methods: In this study we used a validation set of 10 patients (6 positive controls previously characterized by
Sanger-sequencing and 4 negative controls) to assess the analytical sensitivity and specificity of the targeted NGS.
As second step, a training set of 80 enrolled patients with a clinical suspect of RASopathies has been tested. Targeted
NGS has been successfully applied over 92% of the regions of interest, including exons for the following genes:
PTPN11, SOS1, RAF1, BRAF, HRAS, KRAS, NRAS, SHOC, MAP2K1, MAP2K2, CBL.
Results: All expected variants in patients belonging to the validation set have been identified by targeted NGS
providing a detection rate of 100%. Furthermore, all the newly detected mutations in patients from the training
set have been confirmed by Sanger sequencing. Absence of any false negative event has been excluded by
testing some of the negative patients, randomly selected, with Sanger sequencing.
Conclusion: Here we show how molecular testing of RASopathies by targeted NGS could allow an early and
accurate diagnosis for all enrolled patients, enabling a prompt diagnosis especially for those patients with mild,
non-specific or atypical features, in whom the detection of the causative mutation usually requires prolonged
diagnostic timings when using standard routine. This approach strongly improved genetic counselling and
clinical management.
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Noonan syndrome (NS, OMIM 163950) is an autosomal
dominant developmental disorder [1] with a prevalence
ranging between 1:1.000 and 1:2.500 live births [2]. This
disorder is characterized by wide phenotype variability
and shares some clinical features, as facial dysmorph-
isms, congenital heart defect (CHD), postnatal growth* Correspondence: francescaromana.lepri@opbg.net
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stated.retardation, ectodermal and skeletal defects, and variable
cognitive deficits [1,2], with other rare conditions, including
LEOPARD syndrome (LS, OMIM 151100) [3], cardiofacio-
cutaneous syndrome (CFCS, OMIM 115150) [4], Noonan-
like syndrome with loose anagen hair (NS/LAH, OMIM
607721) [5], and Costello syndrome (CS, OMIM 218040)
[6]. This group of related disorders is caused by germline
mutations in distinct genes, encoding for components of
the RAS-MAPK signalling pathway. Based on common
pathogenetic mechanisms and clinical overlap, these
diseases have been grouped into a single family, the so-d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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recently coined RASopathies [7,8]. NS is associated with
PTPN11, SOS1, KRAS, NRAS, RAF1, BRAF, SHOC2,
MEK1 and CBL gene mutations [9-19], LS with PTPN11,
RAF1 and BRAF gene mutations [13,17,20,21], NS/LAH
with SHOC2 gene mutations [22], CFCS with KRAS,
BRAF, MEK1 and MEK2 gene mutations [23,24], CS with
HRAS gene mutations [25].
So far, the molecular characterization can be reached
in approximately the 75-90% of affected individuals. Some
distinct phenotypes are emerged in association with
definite gene mutations.
Nowadays, due to high genetic heterogeneity of these
disorders, which affect genes that all together span about
30 kb of genomic DNA, the standard diagnostic testing
protocol requires a multi-step approach, using Sanger
sequencing. The selection of the genes to investigate on
a first diagnostic level depends on the frequency of their
association with this disorder and their relationship with
a distinct phenotype. For this reason, accurate clinical
evaluation and close interaction between clinical and
molecular geneticists are mandatory for selecting the
genes to be first studied. By using this approach, the
causative mutations can be identified in most of the cases.
Some mutations cannot be identified during the first
screening level since some phenotypes may be related to
mutations in different causative genes or some clinical
features associated with NS related disorders may not
be evident at younger ages, or some extremely rare
mutations are not routinely screened at first analysis.
To detect these mutations, an additional screening level
is required with a second panel of genes, which again
should be guided by clinical geneticist. In these latter
cases the molecular diagnosis requires a longer time
before identifying the pathogenic mutation. Moreover,
standard Sanger sequencing for multiple genes is also an
expensive technique. Based on these notions, genetically
heterogeneous disorders demand innovative diagnostic
protocols, in order to be able to identify disease-causing
mutations in a rapid and routinely way.
Here we report our personal experience on the use of
targeted Next Generation Sequencing (NGS) for diagnosis
of RASopathies. Our study suggests that this protocol
can be easily used as a standard diagnostic tool to iden-
tify disease-causing mutations, with a straightforward




Between June 2012 and June 2013, 80 patients (35 males
and 45 females) with a clinical suspect of any RASopathy
were consecutively enrolled in this study. Mean age
was 8 years (range 2 months - 16 years). All patientshad complete physical examination for major and minor
anomalies by trained clinical geneticists (MCD, BD,
RC). Two-dimensional Color-Doppler echocardiography,
renal ultrasonography, and neurological/neuropsychiatric
assessment for developmental delay or cognitive impair-
ment were routinely performed. Clinical inclusion criteria
were facial anomalies suggestive for RASopathies (pres-
ence of six or more features among hypertelorism, down-
slanting palpebral fissures, epicanthal folds, short broad
nose, deeply grooved philtrum, high wide peaks of the
vermilion, micrognathia, low-set and/or posteriorly angu-
lated ears with thick helices, and low posterior hairline)
[26], associated with almost one of the following clinical
features: short stature, organ malformation (congenital
heart defect or renal anomaly), developmental delay or
cognitive deficit. All patients had normal standard chromo-
some analysis and array-CGH at a resolution of 75 kb.
A total of 10 DNA samples including 6 positive controls
and 4 negative controls, previously characterized by stand-
ard Sanger sequencing were used as a validation set for
establishing the amplicon resequencing workflow and
assessing the analytical sensitivity and specificity of the
targeted NGS. A second group of 80 DNA samples,
extracted from patients manifesting the RASopathies
phenotype, was used as training set. The patient’s genomic
DNA was extracted from circulating leukocytes according
to standard procedures and quantified with fluorescence-
based method. Informed consent was obtained from
the patients’ parents. The study was approved by the
institutional scientific board of Bambino Gesù Children
Hospital and was conducted in accordance with the
Helsinki Declaration.
Targeted resequencing
Targeted resequencing was performed using a uniquely
customized design: TruSeq® Custom Amplicon (Illumina,
San Diego, CA) with the MiSeq® sequencing platform
(Illumina, San Diego, CA). TruSeq Custom Amplicon
(TSCA) is a fully integrated DNA-to-data solution, in-
cluding online probe design and ordering through the
Illumina website sequencing assay automated data ana-
lysis and offline software for reviewing results.
Probe design
Online probe design was performed by entering target gen-
omic regions into Design Studio (DS) software (Illumina,
San Diego, CA). Probe design (Locus Specific Oligos) was
automatically performed by DS using a proprietary algo-
rithm that considers a range of factors, including GC
content, specificity, probe interaction and coverage. Once
the design was completed, a list of 500 bp candidate
amplicons (short regions of amplified DNA) was gener-
ated and the quality of each amplicon design assessed
based on the predicted success score provided by DS.
Figure 1 Screenshots of the designed panel within DS software.
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the operator to edit and improve the predicted success
score to a minimum value of 60%. All exons with a
lower success score have been removed from the design
and excluded from the final TSCA panel. The design
was performed over a cumulative target region of
57,932 bp and generated a panel of 244 amplicons with
a coverage of 98% of the cumulative region (Figure 1).
The choice of genes investigated in this panel has been
made based on scientific evidence for a causative role
in the disease [9-25]. The list of the 11 genes, for a total
of 132 exons, is reported in Table 1.Library preparation and sequencing
TSCA kit generates desired targeted amplicons with the
necessary sequencing adapter and indices for sequencing
on the MiSeq® system without any additional processing.
Library preparation and sequencing runs have been
performed according to manufacturer’s procedure.Table 1 List of genes analyzed in this study and coverage per
Gene PTPN11 SOS1 BRAF
Number of exons uploaded into DS 15 23 18
Number of exons entirely covered by DS
with predicted success score >60%
14 23 18
Total exons covered by DS/ total exons
uploaded into DS (%)
Number of exons successfully sequenced
with coverage > 30
13 22 16
Total exons successfully sequenced/ total
exons covered by DS (%)Data analysis
The MiSeq® system provides fully integrated on-instru-
ment data analysis software. MiSeq Reporter software
performs secondary analysis on the base calls and Phred-
like quality score (Qscore) generated by Real Time
Analysis software (RTA) during the sequencing run.
The TSCA workflow in Miseq Reporter evaluates short
regions of amplified DNA (amplicons) for variants through
the alignment of reads against a “manifest file” specified
while starting the sequencing run. The manifest file is
provided by Illumina and contains all the information
on the custom assay. The TSCA workflow requires the
reference genome specified in the manifest file (Homo
sapiens, hg19, build 37.2). The reference genome provides
variant annotations and sets the chromosome sizes in the
BAM file output. The TSCA workflow performs demulti-
plexing of indexed reads, generates FASTQ files, aligns
reads to a reference, identifies variants, and writes output
files to the Alignment folder. SNPs and short indels are
identified using the Genome Analysis Toolkit (GATK), bycentage of the investigated exons
RAF1 KRAS NRAS HRAS SHOC2 MAP2K1 MAP2K2 CBL
16 5 4 5 8 11 11 16
16 5 3 5 8 11 11 16
98.5
16 5 3 5 8 9 9 14
92.4%
Figure 2 Flowchart of how the analysis was carried out.
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variants against known variants, and then calculates a
false discovery rate for each variant. Variants are flagged
as homozygous (1/1) or heterozygous (0/1) in the Variant
Call File sample column. Because a SNP database (dbSNP
(http://www.ncbi.nlm.nih.gov/projects/SNP) is available in
the Annotation subfolder of the reference genome folder,
any known SNPs or indels are flagged in the VCF output
file. A reference gene database is available in the Annota-
tion subfolder of the reference genome folder and any SNPs
or indels that occur within known genes are annotated.
Each single variant reported in the VCF output file has
been evaluated for the coverage and the Qscore and
visualized via Integrative Genome Viewer (IGV) [27,28].
Based on the guidelines of the American College of
Medical Genetics and Genomics [29], all regions that
have been sequenced with a sequencing depth <30 have
been considered not suitable for analysis. Furthermore
we established a minimum threshold in Qscore of 30
(base call accuracy of 99.9%).
Sanger sequencing validation
All mutations identified by Miseq Reporter have been
validated by Sanger sequencing using standard protocolsTable 2 List of patients with known mutations included in th
Patient ID Gene Mutation Allele state Mu
1 PTPN11 Y63C het
2 PTPN11 N308D het
3 PTPN11 T468M het
4 SOS1 M279R het
5 SOS1 I733N het
6 HRAS G12A hetand, where possible, family members were tested to detect
the “de novo” origin of the mutation. Figure 2 shows the
flowchart of the above described method.
Results
TSCA performance
All coding regions for genes reported in Table 1 have been
uploaded into DS for a total of 132 exons (cumulative tar-
get region of 57,932 bp). The 98.5% of the exons uploaded
were covered by the amplicon design, with a predicted
success score ≥60%. The remaining exons not entirely cov-
ered by DS or with a predicted success score <60% have
been excluded from final TSCA content panel. TSCA se-
quencing runs generated 120 exons successfully and steadily
sequenced (sequencing depth >30, Qscore >30), providing a
total coverage of 91% of the overall of the exons uploaded
into DS, and a coverage of 92% when referring to the
number of exons covered by DS (Table 1). The TSCA
approach reduced up to 12 the number of exons requiring
the standard Sanger sequencing analysis.
Validation set
TSCA sequencing of 4 negative control confirmed the
absence of any variant and the analysis of 6 positivee validation set
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and the allele state. All variants were identified with a
mean coverage of 318 and a mean Qscore = 38, providing
a detection rate of 100% for the validation set (Table 2).
Both positive and negative control samples did not
highlight any further unexpected variant, confirming theTable 3 Mutations identified by TSCA sequencing in patients
Case Phenotype Gene Mutation Protein substitution A
1 NS PTPN11 c.184 T > G Y62D
2 NS PTPN11 c.188A > G Y63C
3 NS PTPN11 c.188A > G Y63C
4 NS PTPN11 c.188A > G Y63C
5 NS PTPN11 c.317A > C D106A
6 NS PTPN11 c.328G > A E110K
7 NS PTPN11 c.417 G > C E139D
8 NS PTPN11 c.661A > G I221V
9 NS PTPN11 c.767A > G Q256R
10 NS PTPN11 c.854 T > C F285S
11 NS PTPN11 c.922 A > G N308D
12 NS PTPN11 c.922 A > G N308D
13 NS PTPN11 c.922 A > G N308D
14 NS PTPN11 c.922 A > G N308D
15 NS PTPN11 c.923 A > G N308S
16 NS PTPN11 c.1183G > T D395Y
16 NS PTPN11 c.1186 T > C Y396H
17 NS PTPN11 c.1226G > C G409A
18 NS PTPN11 c.1282G > T V428L
19 LS PTPN11 c.1403C > T T468M
20 LS PTPN11 c.1492 C > T R498W
21 LS PTPN11 c.1492 C > T R498W
22 NS SOS1 c.755 T > C I252T
23 NS SOS1 c.806 T > G M269R
24 NS SOS1 c.806 T > G M269R
25 NS SOS1 c.1310 T > A I437N
26 NS SOS1 c.1649 T > C L550P
27 NS SOS1 c.1649 T > C L550P
28 NS SOS1 c.2104 T > C Y702H
29 NS SOS1 c.2371C > A L791I
30 NS SOS1 c.2371C > A L791I
31 NS/CFCS BRAF c.1694A > G D565G
32 CFCS BRAF c.1802A > T K601I
33 CFC MEK2 c.326C > T A110 T
34 CFC MEK2 c. 395 T > G G132D
35 NS RAF1 c.785 A > T N262I
36 NS RAF1 c.781C > T P261S
37 NS CBL c.2350G > A V784M
p.s: present study.absence of any unreported variant in the validation set,
and of any false positive result.
Training set
Samples from training set were investigated in three
different sequencing runs, with an average coverage ofenrolled in the training set
llele state Variant frequency Coverage Qscore Reference
het 0.448 460 39 [30]
het 0.521 190 39 [9]
het 0.54 512 39 [9]
het 0.481 1046 38 [9]
het 0.495 632 39 [31]
het 0.486 702 36 [31]
het 0.498 406 38 [30]
het 0.482 737 39 p.s
het 0.514 290 36 p.s
het 0.406 64 39 [30]
het 0.526 812 38 [9]
het 0.508 1174 39 [9]
het 0.505 3126 39 [9]
het 0.486 3111 39 [9]
het 0.555 119 40 [30]
het 0.556 561 38 p.s
het 0.557 560 37 p.s
het 0.444 178 38 [32]
het 0.502 416 38 p.s
het 0.467 319 40 [20]
het 0.573 185 35 [33]
het 0.521 142 38 [33]
het 0.528 212 39 [34]
het 0.564 140 38 [34]
het 0.496 391 38 [34]
het 0.46 302 40 [34]
het 0.516 275 39 [34]
het 0.428 428 39 [34]
het 0.52 421 37 [34]
het 0.576 363 37 p.s
het 0.546 108 39 p.s
het 0.463 341 39 p.s
het 0.538 1120 37 [17]
het 0.505 299 37 p.s
het 0.533 227 38 [35]
het 0.504 135 39 p.s
het 0.524 143 39 [13]
het 0.428 173 36 p.s
Figure 3 An example of three different mutations (A. PTPN11:Y63C; B. SOS1: M269R; C. BRAF: K601I) identified by Miseq.
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were identified in 6 of the 11 RAS pathway genes ana-
lyzed, PTPN11 (22/38 = 58%), SOS1 (9/38 = 23%), BRAF
(2/38 = 5%), MEK2 (2/38 = 5%), RAF1 (2/38 = 5%), CBL
(1/38 = 3%). The 38 variants identified from Miseq Re-
porter had an average coverage of 595x and an average
Qscore of 38 (Table 3).
All variants have been confirmed by Sanger sequencing
and IGV, indicating the absence of any false positive result
in the training set group (Figure 3). Moreover, to exclude
any possible false negative event, 10 negative samples
randomly selected, have been further analyzed by Sanger
sequencing (only “hot spots” exons) and 30 additional
samples have been analyzed for PTPN11, using NGS
and Sanger sequencing and all of them provided nega-
tive results.Figure 4 Performance of the same target (PTPN11_exon8) region thro
third run).Reproducibility
TSCA sequencing showed 100% reproducibility for all 120
exons, independently from DNA samples and sequencing
runs, making this approach compatible with a diagnostic
purpose. Figure 4 illustrates the performance of the same
target region through three sequencing runs.
Discussion
The term RASopathy applies to a group of genetic disor-
ders characterized by similar phenotypes, caused by muta-
tions in the RAS MAPK pathway. These phenotypes are
characterized by a high degree of genetic heterogeneity,
since individual diseases can arise from mutations in differ-
ent genes. In addition, since different RASopathies share
similar clinical features, their molecular characterization is
complex, time consuming and expensive.ugh 3 different sequencing runs (A. first run; B. second run; C.
Table 4 Clinical features of the patients carrying rare PTPN11 mutations
Case n°8 Case n°9 Case n°10 Case n°16 Father case n°16 Case n°18 Mother case n°18
Sex
Short stature
Macrocephaly + - + - -
Hypertelorism
Downslanting palpebral fissures
Palpebral ptosis - - + - + + +
Epicanthal folds + + - + -
Short broad nose + + - + - -
Deeply grooved philtrum + + + + +
High wide peaks of the vermilion + + + + + + +
Micrognathia - + -
Low-set and/or posteriorly angulated
ears with thick helices
Low posterior hairline - + + - - + -
Thorax anomalies - + + - - + -
Cardiac defect + + - - -
- PVS - + + - - - -
- ASD - - -
- VSD - - - - -
- PDA - + - - -
Arrhythmia - - - - - WPW -
Renal anomaly - - - - - - -
Cryptorchidism NA - - + NA
Developmental delay or cognitive deficit
Alopecia - - + + -
Pancreatic cyst + - - - -
Angioma - - - - -
Inheritance NT pat NT mat NT
ASD, atrial septal defect; VSD, ventricular septal defect; HCM, hypertrophic cardiomyopathy; mat, maternal; NA, not applicable; NT, not tested; pat, paternal; PDA,
patent ductus arteriosus; PVS, pulmonary valve stenosis; WPW, Wolf-Parkinson-White.
+present; -not present.
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thies, in this study we investigated a protocol based on a
targeted NGS using MiSeq Illumina platform enabling the
analysis of all known causative genes in up to 96 patients
in a single sequencing run. In particular, we analyzed
80 patients and identified 38 mutations in 6 of 11 RAS-
pathway genes, including PTPN11 (22/38 = 58%), SOS1
(9/38 = 23%), BRAF (2/38 = 5%), MEK2 (2/38 = 5%),
RAF1 (2/38 = 5%), CBL (1/38 = 3%). The relative frequency
of mutations in the tested genes was in agreement with
published results [30,36,37]. As shown in Table 3, in
many patients the causal mutation was identified in the
gene considered the most suitable candidate, based on
frequency of mutations and the phenotypic characteristics.
As expected, most NS patients had a PTPN11 mutation,
while the second most frequently mutated gene was SOS1,followed by RAF1. Three patients with LEOPARD syn-
drome had one of the PTPN11 recurrent mutation pre-
viously associated with this phenotype (T468M or
R498W) [20,33]. Among patients heterozygous for a
pathogenic BRAF mutation, one was clinically diagnosed
as being affected by CFCS, while in the other case clinical
evaluation was unable to conclude whether he was
affected by NS or CFCS. The patients’ age at diagnosis
is obviously important: this latter subject was 2 year-old at
time of clinical evaluation, when he displayed only some
features of CFCS [38]. Two other patients with CFCS
had a mutation in MEK2 gene, which is less commonly
mutated in this disorder. In addition, one NS patient
had a mutation in CBL, a gene rarely associated with
this disorder. Since all genes have been analyzed in
one run, the present protocol allowed to reach the
Figure 5 Comparison of time (A) and cost (B) between NGS and Sanger sequencing.
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the most frequent and rare genes, with a significantly
reduction of time needed to reach the molecular
characterization of the patient. This point is important
for early diagnosis and classification of the different
RASopathies, allowing a more appropriate management
and counseling.
A wide spectrum of PTPN11 mutations has been asso-
ciated with NS, including some rare mutations: I221V,
Q256R, F285S, V428L (Table 4). All these variants are
associated with the distinct facial gestalt of NS, which
was markedly expressed in one patient (case no.10) with
F285S and mildly expressed in the others. Familial trans-
mission from an affected individual has been found in
one instance, and suspected in another case (no.8), where
the affected proband’s brother was referred to have
membranous subaortic stenosis and cryptorchidism. Men-
tal retardation or cognitive deficit was not associated with
these mutations, with the exception of F285S mutation.
Interestingly, the patient heterozygous for this latter
mutation had a congenital pancreatic cyst, an unusual
malformation in the RASopathies. In one patient (case
no.16) we identified two unpublished mutations affecting
two consecutive PTPN11 aminoacids, D395Y and Y396H.
Both mutations were inherited from the affected father.
Variability of clinical expression in this family was recog-
nizable, since facial anomalies of NS were associated
with developmental delay in the son only. The father
had congenital total alopecia as distinctive feature. It isevident that the phenotype related to these mutations
is quite atypical, showing common Noonan-like facial
anomalies associated with variable additional neural and
ectodermal features.
The other 43 patients enrolled in this study were nega-
tive for the investigated RAS genes. The proportion of
negative patients was higher compared to previous reports,
likely because clinical inclusion criteria were less stringent
compared to other studies [39-41], being based on NS
facial anomalies and almost only one additional feature.
Interestingly, the mother of patient n°18 was included
in this study being the mutated parent of an affected
child, although the minimal clinical criteria for diagnosis
of NS were not present.
All the variations have been confirmed by Sanger se-
quencing as well as the 4 negative control patients. These
data indicated a 100% detection rate of mutations involved
in RASopathies and, most important, all these results have
been obtained with MiSeq on board analysis, being the
bioinformatics examination performed only adopting
the user friendly Miseq Reporter software.
The absence of any false negative and false positive
results and the possibility to have an easy and accurate
data analysis make this approach a good diagnostic tool.
Furthermore, the library preparation workflow is easy
and the TSCA kit performance is stable. In fact, all
different experiments for the RAS pathway genes in each
run provided the same results in terms of coverage and
quality (Figure 4).
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protocols include the time needed to complete the entire
workflow and the costs that this approach requires. Tar-
geted NGS analysis of the complete coding sequences of
the 11 genes in the RAS pathway for 96 patients takes
about two months, including ten days for library prepar-
ation and data analysis and about 45 days to characterize
uncovered regions using Sanger sequencing. Conversely,
the use of Sanger sequencing to analyze the full coding
sequence of the 11 genes would take about 16-18 months
for the same number of patients. We also calculated that
the cost of NGS analysis applied to the 92% of the regions
of interest, plus Sanger sequencing of for the remaining
regions, would cost 6 time less than the cost of a protocol
entirely based on Sanger sequencing (Figure 5). However,
time and cost could be further reduced, by designing a
new panel which includes also RIT1, a gene recently
associated to NS [42], resulting in a 100% coverage of
the cumulative region. This result likely makes the Sanger
sequencing irrelevant for the analysis, further reducing
the time and the cost of the entire process.
Conclusion
This study demonstrates that NGS can be successfully
applied to the molecular testing of RASophaties with a
remarkable gain of time and less cost, while maintaining
the high quality of the results. Consistent with available
records, our data confirm that the genetic mechanism
underlying the RASopathies is due to germline mutations
in different genes encoding for components of the RAS-
MAPK signalling mutations, with PTPN11, followed by
SOS1, being the most frequently mutated genes in our
cohort. Moreover, the use of NGS protocol has allowed,
with a high standard in terms of coverage and quality,
an early detection of rare mutations in other RAS-MAPK
genes, avoiding the use of standard Sanger sequencing
approach and the related enlarged cost and time consum-
ing issues. Taken all together, these data highlight the
usefulness of a molecular characterization that lead to
an early diagnosis especially for patients with mild,
nonspecific or atypical features and might direct to a more
appropriate genetic counselling and clinical management.
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